Courtesy: Dr Alana Serota, Dr Ashok Shyam, Ortho TV

Metabolic Bone Health & Perioperative Optimization in Orthopedic Surgery

The Sentinel Fracture Concept & “Own the Bone”

• The Sentinel Event: A fragility fracture is a sentinel systemic event analogous to a myocardial infarction; just as an MI mandates cardiological intervention, a fragility fracture requires formal metabolic bone evaluation.

• The “Leaning Tower of Pisa” Principle: Even the most technically sound orthopedic implant fixation will fail if the underlying biological foundation is compromised; postoperative complications often stem from defective host bone rather than surgical technique.

• Intraoperative Bone Assessment: Subjective surgeon feedback (e.g., bone behaving like “Swiss cheese” during reaming or screw insertion) correlates strongly with microarchitectural degradation and warrants immediate postoperative referral.

Epidemiology & Structural Vulnerabilities in India

• Prevalence Benchmarks: Affects approximately 20% of women over age 50, escalating to 64% in elderly cohorts; male osteoporosis remains substantially underdiagnosed and undertreated.

• Unique Regional Drivers:

  • Accelerated onset of menopause occurring roughly 5 years earlier than Western cohorts.

  • Lower lifetime peak bone mass (established by age 18) compared to standard Caucasian reference databases.

  • Endemic vitamin D receptor (VDR) polymorphisms affecting calcium handling.

  • Rising urbanization contributing to increasingly sedentary lifestyles.

• Morbidity and Mortality: India sees approximately 500,000 hip fractures annually; 1-year mortality following an osteoporotic hip fracture exceeds that of an acute myocardial infarction.

• Infrastructure Deficits: Diagnostic dual-energy X-ray absorptiometry (DEXA) availability is severely limited (0.25 scanners per million population versus the recommended standard of >10 per million).

• Population Awareness: Community awareness remains under 10% to 15%, resulting in widespread undertreatment even after an index fracture.

Diagnostic Criteria & Quality Markers

• WHO T-Score Diagnostic Categories:

  • Normal bone density: T-score $\ge -1.0$.

  • Osteopenia (low bone mass): T-score between $-1.0$ and $-2.5$.

  • Osteoporosis: T-score $\le -2.5$ at any of the standard anatomical regions (lumbar spine, femoral neck, total hip, or 33% radius).

  • Severe / Established Osteoporosis: T-score $\le -2.5$ combined with a sustained fragility fracture.

• Clinical Diagnostic Equivalents (Osteoporosis by Definition regardless of DEXA):

  • A hip fracture resulting from a low-energy ground-level fall.

  • Osteopenia combined with a high FRAX score meeting intervention thresholds.

  • Low-trauma clinical vertebral, proximal humerus, or pelvic fractures in patients with osteopenia.

  • Low-energy distal radius fractures sustained from simple falls (e.g., slipping on domestic marble floors vs. high-energy sports trauma).

• Trabecular Bone Score (TBS):

  • Evaluates grey-level textural variations from lumbar spine DEXA scans, measuring trabecular microarchitectural quality independent of areal bone mineral density (BMD).

  • Categorized as normal, partially degraded, or degraded.

  • Critical orthopedic advantage: TBS is not artificially elevated by osteophytes, facet arthrosis, or vascular calcifications, providing an accurate assessment in spondylotic spines.

  • Demonstrates the greatest structural improvement when patients are treated with osteoanabolic agents.

• Fracture Risk Assessment Tool (FRAX):

  • Country-specific risk engine usable without bone mineral density inputs in resource-scarce regions.

  • Standard intervention thresholds: 10-year probability $\ge 20\%$ for a major osteoporotic fracture (MOF) or $\ge 3\%$ for a hip fracture.

  • India-adjusted presurgical screening threshold: MOF risk $>8.4\%$.

Arthroplasty Implications: Fixation & Periprosthetic Risk

• High Unrecognized Prevalence: Between 20% and 25% of elective joint arthroplasty patients have undocumented osteoporosis; only roughly 5% receive preoperative medical therapy.

• Diagnostic Blind Spots: Osteoarthritic joint sclerosis masks systemic osteopenia on plain radiographs; furthermore, higher BMI patients are frequently misassumed to possess healthy bone stock.

• Cemented vs. Uncemented Fixation:

  • Total Knee Arthroplasty (TKA): High-risk osteoporotic patients benefit substantially from cemented tibial and femoral fixation to prevent early subsidence.

  • Total Hip Arthroplasty (THA): Recent comparative data indicates modern uncemented tapered wedge femoral stems perform comparably to cemented stems in osteopenic bone, challenging the assumption that all osteoporotic hips mandate cementation.

• Periprosthetic Fracture Risk: Pre-existing osteoporosis directly drives postoperative periprosthetic fractures around both hip and knee implants; proactive medical treatment significantly reduces secondary periprosthetic fracture rates.

Perioperative Lifestyle & Nutritional Optimization

• Vitamin D Repletion: Target maintenance dosing of 1,000 to 2,000 IU daily in Indian cohorts; utilize Vitamin D2 (ergocalciferol) in strict vegetarian/vegan populations where lanolin-derived D3 is unacceptable.

• Calcium Balancing: Target daily dietary calcium intake of 600 to 1,000 mg; restrict pharmacological calcium supplements strictly to bridging dietary shortfalls to avoid cardiovascular hypercalcemic risks.

• Neuromuscular Conditioning: Daily weight-bearing and balance conditioning (e.g., single-leg unipedal standing while brushing teeth) to improve proprioception.

• Environmental Fall-Risk Reduction: Correcting unaddressed visual deficits, treating hearing loss (a 25 dB hearing deficit increases fall risk threefold due to impaired spatial orientation), removing home trip hazards, and providing nighttime path lighting.

• Hormone Therapy Management: Transdermal hormone replacement therapy bypasses hepatic first-pass metabolism without upregulating clotting factors; it does not heighten deep vein thrombosis risk and does not require routine perioperative discontinuation.

Pharmacotherapy: “Bone Growers” vs. “Bone Maintainers”

• Class Distinction:

  • Bone Growers (Osteoanabolics): Rebuild trabecular microarchitecture, restore TBS, and drive osseointegration.

  • Bone Maintainers (Antiresorptives): Suppress osteoclast-mediated bone turnover and preserve existing mineral volume.

• Sequencing Law: In severe disease, always initiate treatment with an osteoanabolic “grower” first before transitioning to an antiresorptive “maintainer”; antiresorptive exposure suppresses the subsequent anabolic window.

• The “Drug Holiday” Rule: Drug holidays are clinically permissible only with bisphosphonates due to their multi-year skeletal half-life.

• Denosumab (Prolia) Discontinuation Warning: Never place a patient on a denosumab drug holiday; abrupt cessation triggers rebound osteoclast activation, precipitous bone loss, and severe multi-level vertebral compression fractures within 6 to 12 months unless promptly transitioned to a potent bisphosphonate.

• Specific Pharmacological Agents:

  • Teriparatide (rhPTH 1-34): Potent daily subcutaneous osteoanabolic agent; achieves the highest fracture risk reduction and drives periprosthetic bone formation and uncemented implant osseointegration.

  • Zoledronic Acid (Reclast): Once-yearly intravenous bisphosphonate delivering continuous bone turnover suppression lasting up to 3 to 5 years; ideal for non-adherent populations.

  • Alendronate (Fosamax): Oral workhorse bisphosphonate; reduces periprosthetic bone loss and all-cause revision rates in lower-extremity arthroplasty registries, though inferior in potency to zoledronic acid and teriparatide.

  • Denosumab: Monoclonal antibody targeting RANKL; reduces periprosthetic bone mineral loss and early implant micromotion, but demands strict administration adherence.

Preoperative Surgical Optimization Algorithm

• Preoperative DEXA Screening Triggers (Indian Cohorts):

  • Females age $\ge 60$ or males age $\ge 65$.

  • Any personal history of low-trauma fragility fracture.

  • Calculated FRAX major osteoporotic fracture risk $>8.4\%$.

• Stratified Risk Management:

  • Low to Intermediate Risk: Ensure baseline calcium and vitamin D repletion; proceed directly with scheduled surgery.

  • High Risk (Established Osteoporosis without Imminent Risk): Initiate antiresorptive or anabolic therapy; proceed with surgery without extended delays while securing postoperative medical follow-up.

  • Very Severe / Imminent Fracture Risk:

    • Defined by: T-score $\le -3.0$, a fragility fracture within the preceding 2 years (imminent fracture window), or FRAX score $>30\%$ major osteoporotic fracture / $>4.5\%$ hip fracture.

    • Protocol: Postpone elective reconstruction for a 3-month optimization window to complete an induction course of an osteoanabolic agent (teriparatide) to restore baseline osseous integrity prior to implant placement.